Search review questions

Blood‐feeding success (washed nets) · Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (washed nets) · Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (washed nets) · Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (washed nets) · Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group

Parasite prevalence (9‐ to 12‐month · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (washed nets) · Anopheles gambiae complex or Anopheles funestus group

Parasite prevalence (16‐ to 18‐month · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Parasite prevalence (21‐ to 25‐month · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (unwashed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (washed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (unwashed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Blood‐feeding success (washed nets) · adults and childen living in malaria‐endemic areas, Anopheles gambiae complex or Anopheles funestus group

Mosquito mortality (unwashed nets) · Anopheles gambiae complex or Anopheles funestus group

All‐cause mortality among participants · people being investigated for tuberculosis (TB)

All‐cause mortality at 6 months (subgroup) · people being investigated for tuberculosis (TB)

All‐cause mortality in people who were HIV‐positive (subgroup) · people being investigated for tuberculosis (TB)

Successful treatment outcome in participants treated for tuberculosis · people being investigated for tuberculosis (TB)

Proportion of participants who were treated for tuberculosis · people being investigated for tuberculosis (TB)

Pre‐treatment loss to · people being investigated for tuberculosis (TB)

Treated participants with bacteriological confirmation of tuberculosis · people being investigated for tuberculosis (TB)

Incidence of clinical malaria · adults and children living in malaria‐endemic areas

Adverse events · adults and children living in malaria‐endemic areas

Mortality · people with bloodstream infections

Mortality (subgroup genotypic) · people with bloodstream infections

Mortality (subgroup phenotypic) · people with bloodstream infections

Mortality (with stewardship) · people with bloodstream infections

Mortality (without stewardship) · people with bloodstream infections

Time‐to‐discharge from hospital (days) · people with bloodstream infections

Time‐to‐appropriate antibiotic · people with bloodstream infections

Death due to any cause · adults with mild to severe COVID‐19

Participants with any adverse events · people who have been exposed to SARS‐CoV‐2

Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2

Negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from enrolmentd · adults with mild to severe COVID‐19

Progression to mechanical ventilation · adults with mild to severe COVID‐19

Time to clinical improvement · adults with mild to severe COVID‐19

Participants with any adverse events · adults with mild to severe COVID‐19

Participants with serious adverse events · adults with mild to severe COVID‐19

Participants with prolongation of QT‐interval on ECG · adults with mild to severe COVID‐19

Development of confirmed COVID‐19 at 14 days from enrolment · people who have been exposed to SARS‐CoV‐2

Hospitalized due to COVID‐19c · people who have been exposed to SARS‐CoV‐2

Index test · children with close tuberculosis contacts Index tests: groups of multiple symptoms Role: an initial test Threshold for…

Specificities 99% and 100% · children evaluated in inpatient or outpatient settings Index tests: Xpert MTB/RIF Role: an initial test Threshold for…

≥ 1 of cough, fever, or poor weight gain · children with close tuberculosis contacts Index tests: groups of multiple symptoms Role: an initial test Threshold for…

≥ 1 of cough, fever, or decreased playfulness · children with close tuberculosis contacts Index tests: groups of multiple symptoms Role: an initial test Threshold for…

≥ 1 of cough, fever, poor weight gain, or tuberculosis close contact (WHO 4‐symptom symptom screen) · children with close tuberculosis contacts Index tests: groups of multiple symptoms Role: an initial test Threshold for…

Estimation (95% Cl) · children with close tuberculosis contacts Index test: abnormal chest radiography Role: an initial test Threshold for…